One of the most exciting aspects of PSMA expression in HCC lesions relies on the concept of PSMA-targeted theragnostic, hence the use of PSMA both as a diagnostic and a therapeutic target. This evidence concerns the gene FOLH1 and hepatocellular carcinoma.